Skip to content
Open access

The Association of Cardiovascular Disease (CVD) with Progression of Advanced Fibrosis Risk in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Sep 2026 · Livers · 0 citations · 37 references

Abstract

Objective: Advanced fibrosis is the best predictor of future severe liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Our study aims to determine the association between cardiovascular disease (CVD) with time to a high-risk Fibrosis-4 Index (FIB-4) in patients with low-risk MASLD. Methods: This retrospective cohort study was conducted at a primary care clinic between 2012 and 2021. The cohort included patients with MASLD and a FIB-4 score at low risk for advanced fibrosis (<1.3). Patients were followed for the outcome of having a high-risk FIB-4 (≥2.67) or until the end of the study period. The primary predictor variable was CVD, a composite of ICD-9/10 codes for coronary artery, cerebrovascular, and peripheral arterial disease. Covariates included demographic and comorbidity variables. Unadjusted and adjusted Cox regression models were developed for the outcome of time to a high-risk FIB-4 score. Results: The cohort included 859 patients with a mean age of 49.6 years (± 13.7) and mean body mass index of 34.1 (± 8.3) kg/m2. The included patients were 70% female and 41% non-white. Of the cohort, 32%, 36%, and 74% had CVD, type 2 diabetes mellitus, and hypertension, respectively. During a mean follow-up of 3.8 (± 2.7) years, 9.3% (80) of the sample had a subsequent high-risk FIB-4 score. The multivariable Cox regression model demonstrated a significant association between CVD (HR 2.13; 95%CI 1.33–3.40) and chronic kidney disease (HR 2.05; 95%CI 1.23–3.42) with the time to transition to a high-risk FIB-4 score. Conclusion: Our study showed that CVD is associated with an increased risk of progression of FIB-4 scores at low to high risk for advanced fibrosis in MASLD patients. Future research investigating how control of cardiometabolic comorbidities impact fibrosis progression in MASLD is warranted.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.